   |
|
 Sri Diah, Ph.D.
IRTA Fellow Tel (919) 316-0478 Fax (919) 541-7560 diah@niehs.nih.gov Curriculum Vitae (http://www.niehs.nih.gov/research/clinical/gei/staff/docs/diah_cv.pdf)  (34 KB)
P.O. Box 12233Mail Drop F3-04 Research Triangle Park, North Carolina 27709 Delivery Instructions Sri Diah, Ph.D., received her bachelor's degree in biochemistry from Virginia Polytechnic Institute and State University (Virginia Tech) in 1994 where she was a World Bank international scholar. She next received her Ph.D. 1999 in biochemistry from the Wake Forest University School of Medicine. Her doctoral thesis focused on the molecular mechanisms of drug resistance in breast cancer cells, with an emphasis on synergy between glutathione S-transferases (GSTs) and multi-drug resistance proteins (MRPs) in conferring resistance to toxic compounds and antineoplastic drugs. In 2000, she began her postdoctoral training at Brown University where she continued her cancer focus by investigating liver tumor progression. This fellowship introduced her to the concept of pharmacogenomics in disease diagnosis and treatment. In 2001, she was granted a fellowship at Harvard University, during which she studied cell cycle mechanisms in tumor progression. Diah joined the laboratory of Perry Blackshear, M.D., D.Phil., at NIEHS in 2002 for a one year fellowship and subsequently joined the Clinical Research Program as an IRTA fellow in 2006. Her current research interests focus on the discovery of single nucleotide polymorphisms (SNPs) in genes that have been implicated in neoplasia as well as autoimmune diseases such as rheumatoid arthritis. Additionally she investigating the functional relevance of these SNPs from a biological viewpoint, i.e. their potential to modulate biological pathway(s) involved in autoimmune or neoplastic diseases. The genes currently under investigation include ZFP36 and ZFP36L2, both of which are in the human tristetraproline family, as well as RecQL, which codes for a human helicase. |
|
   |
|
|